ORLANDO, Florida — Clinicians should keep in mind concerns about overdiagnosis of thyroid cancer when prescribing glucagon-like peptide 1 (GLP-1) drugs, as the US black box...
Nearly 2 years after their final transfusion with the IGF-IR inhibitor teprotumumab (Tepezza), 82% of patients with thyroid eye disease did not need further treatment for...